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MicroRNAs (miRNAs) are small noncoding RNAs that are emerging as pivotal modulators in virtually all aspects of cardiac 
biology, from cardiac development to cardiomyocyte survival and hypertrophy. The miRNA profiling, following gain- and 
loss-of-function studies using in vitro and in vivo models, has identified wide-ranging functions for miRNAs in the heart, 
providing new perspectives on their contributions to cardiac pathogenesis, and revealing potential therapeutic targets and di-
agnostic biomarkers. This review summarizes current progress in regulation of miRNAs in heart development and disease. 
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MicroRNAs (miRNAs) are endogenous small non-coding 
RNAs of approximately 22 nucleotides, which are processed 
from one arm of stem-loop hairpin RNA precursors by the 
action of Dicer, a ribonuclease III-like enzyme [1]. miRNAs 
play an important regulatory role in animals and plants, re-
sulting in gene silencing via inhibition of translation [2] and 
mRNA degradation [3]. It has been estimated that the human 
genome can encode up to 1000 miRNAs, and to date, hun-
dreds have been experimentally identified [1]. Each miRNA 
can target multiple mRNA sites, with several hundred targets 
per miRNA possible, thereby enabling modulation of gene 
expression patterns rather than a single gene. miRNAs have 
been shown to play a role in the regulation of development, 
tissue homeostasis and disease pathogenesis [4].  
1  miRNA in cardiac development   
A large set of miRNAs expressed in the heart have been 
identified by direct cloning [5] and microarray-based pro-
filing [69], with miR-1 and miR-133 found to be highly 
enriched in cardiac and skeletal muscle. miR-1 is most 
abundant in heart, representing 45% of total miRNAs in the 
adult mouse heart and 24% in the adult human heart. Its 
expression coincides with the onset of cardiomyocyte dif-
ferentiation in the developing heart tube, and somitic myo-
tome development in chick embryos [10] and the looping 
mouse heart at embryonic day (E) 8.5, where it is regulated 
by SRF (serum response factor) [11]. Two members of the 
miR-1 class of RNAs, miR-1-1 and miR-1-2, are specifi-
cally expressed in cardiac tissue and skeletal muscle. 
miR-1-1 and miR-1-2 are encoded separately by different 
chromosomes but appear to target the same mRNAs. To 
determine the particular role of miR-1-2, Zhao et al. [11] 
used a targeted deletion strategy to eliminate the miR-1-2 
locus without affecting adjacent genes. Approximately 50% 
of mice lacking miR-1-2 died during embryonic develop-
ment, showing abnormal morphogenesis, including ventric-
ular septal defects [12]. 
In Drosophila, dmiR-1 is expressed in the mesoderm 
during embryonic development (stage 5) and subsequently 
in all its muscle cell derivates including the dorsal vessel  
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[13]. Using a conditional knockout strategy, dmiR-1 was 
shown to be critical for muscle development [13]. Con-
versely, in rodent heart, miR-1 is essential for cardiogenesis, 
with overexpression of miR-1 in a transgenic model driven 
by the beta myosin heavy chain (β-MHC) promoter, leading 
to developmental arrest at E13.5.  
miR-1 targets Hand2, a transcription factor responsible 
for the regulation of embryonic cardiac ventricle expansion; 
therefore it is feasible that the phenotype observed in em-
bryonic rodent heart is due to the reduction of endogenous 
Hand2 by excess miR-1 [11]. Furthermore, miR-1 functions 
have been addressed using singular genomic ablation strate-
gies. The resulting homozygous knockout mice were lethal 
in development (E15.5) and early neonatal life, with no ob-
served effect on the survival of heterozygous animals [12], 
likely because of compensation for miR-1 reduction by the 
second gene. Ventricular septal defect was the leading cause 
of lethality in half of homozygous embryos. Of the remain-
ing mice, 15% survived early lethality; however, wall 
thickening due to hyperplasia, accompanied by prolongation 
of the action potential and occasional sudden death, was 
observed in these animals. This may be explained by the 
reduction in Irx5, a negative transcriptional regulator of the 
potassium channel Kcnd2/Kv4.2, by excess miR-1 [12], 
leading to repolarization defects and subsequent electrical 
conduction abnormality [14].  
miR-133 is another muscle-enriched miRNA, although 
its abundance in heart is less than miR-1. In contrast to 
miR-1, with deletion of one or two miR-1 genes resulting in 
lethality in knockout mice, deletion of one heart expressed 
gene of miR-133 had no effect on heart development. Fol-
lowing targeted deletion of miR-133a-1 or miR-133a-2, no 
obvious cardiac morphological and functional abnormalities 
were observed, likely because of the redundant action of the 
genes, with each gene accounting for approximately 50% of 
function [15]. However, combined targeted deletion of 
miR-133a-1 and miR-133a-2 resulted in embryonic and 
postnatal lethality. This early mortality correlated with ven-
tricular septal defects and enlargement of the right ventricle 
and atria due to development of dilated cardiomyopathy and 
increased fibrosis [15].  
The phenotypic abnormalities of the miR-133a-1/miR- 
133a-2 knockout mice result from the upregulation of SRF 
and cyclin D2, two of the downstream targets of miR-133, 
leading to ectopic expression of smooth muscle genes in 
heart tissue, aberrant cardiomyocyte proliferation and 
apoptosis. Moreover, transgenic miR-133a overexpression 
in heart resulted in thinning of ventricular walls, an insuffi-
cient pumping action of the heart and embryonic lethality 
(E15.5) [15] (Figure 1).  
2  miRNA in heart disease 
2.1  Cardiac hypertrophy 
There are two forms of cardiac hypertrophy: (i) physiologi- 
cal, the normal response to healthy exercise or pregnancy 
which results in an increase in myocardial mass and pump-
ing ability; (ii) pathological, the size of the heart initially 
increases to compensate for damage to the heart due to 
metabolic abnormality, stress or disease, but subsequently 
leads to a decline in left ventricular function [16]. Patho-
logical hypertrophy is associated with all forms of heart 
failure observed in the clinical setting. Hence, to understand 
its underlying mechanism is of great importance for drug 
development to cure cardiac disease. Pathological hyper-
trophy is mainly caused by hypertension, loss of myocytes 
subsequent to myocardial infarction (MI) or ischem-
ic/reperfusion (I/R) injury, and genetic alterations that lead 
to enlargement of the left ventricles, such as dilated cardi-
omyopathy. Moreover, metabolic abnormality or stress can 
also lead to hypertrophy [17]. Currently, there is great in-
terest in determining the molecular mechanisms, including 
the roles of miRNAs, in pathological hypertrophy (Figure 1). 
Using animal models, genome wide miRNA microarrays 
have been used to isolate miRNAs which are upregulated, 
downregulated or remain unchanged, in cardiac hypertrophy 
compared with a normal heart [1824]. From these studies, 
certain miRNAs are more frequently reported by different 
research groups, indicating the possibility that these miR-
NAs might have common roles in hypertrophy pathogenesis. 
Among the frequently reported miRNAs, miR-21, miR-23a, 
miR-24, miR-125, miR-129, miR-195, miR-199, miR-208 
and miR-212 are often upregulated with hypertrophy, 
whereas miR-1, miR-133, miR-29, miR-30 and miR-150 are 
often downregulated. Interestingly, transgenic overexpres-
sion of individual miRNAs, including miR-23a, miR-23b, 
miR-24, miR-195, miR-199a and miR-214, all upregulated 
with cardiac hypertrophy, was sufficient to induce cardiac 
hypertrophy. Furthermore, in a knock-in mouse model, 
overexpression of miR-195 was sufficient to drive patho-
logical cardiac growth [18]. By contrast, in vitro overex-
pression of miR-150 and miR-181b, both downregulated in 
cardiac hypertrophy, resulted in reversal of cardiomyocyte 
size [18]. The ability of individual miRNAs to mimic car-
diac phenotypes implies that the different miRNA is a cause 
rather than simply a consequence of pathologic cardiac re-
modeling. 
Although high-throughput miRNA microarray or RNA 
sequencing have identified a set of miRNAs involved in 
cardiac hypertrophy, the transcriptional mechanism that 
regulates the expression of miRNAs responsible for cardiac 
hypertrophy needs further investigation. Transcriptional 
regulation of miRNAs is well studied for miR-1 ⁄miR-133. 
SRF is a cardiac-enriched transcription factor responsible 
for the regulation of organized sarcomeres in the heart [25]. 
SRF interacts synergistically with myocardin to activate 
miR-1-1 and miR-1-2 by binding to the upstream SRF- 
binding consensus element CArG box [11]. Myocyte en-
hancer factor-2 (MEF2) also activates transcription of the  
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Figure 1  Critical roles of the miR-1/miR-133 cluster in muscle development. The tissue-specific expression of miR-1 and miR-133 clusters is driven by 
the transcription factors SRF, MEF2 and MyoD. miR-1 promotes muscle differentiation by repressing the expression of HDAC4 (histone deacetylase 4). 
HDAC4, in turn, binds and inhibits activation of the critical muscle transcription factor, MEF2 (myocyte enhancer factor-2), which potently activates the 
expression of myoblast differentiation genes and miR-1. miR-133 causes downregulation of SRF, a crucial regulator of muscle differentiation, and enhances  
the proliferation of myoblasts, inhibiting their differentiation. 
bicistronic precursor RNA encoding miR-1-2 and miR- 
133a-1, via an intragenic muscle-specific enhancer [26]. It 
was reported that nuclear factor of activated T cells isoform 
3 (NFATc3), well known as a key factor in mediating the 
hypertrophic signal of calcineurin [27], transactivates the 
expression of miR-23a by binding directly to the promoter 
region of miR-23a, which subsequently suppresses transla-
tion of muscle specific zinc finger protein 1 [28]. miR-1 
negatively regulates the expression of hypertro-
phy-associated calmodulin, MEF2a and GATA4, attenuat-
ing calcium-dependent signaling through the calcineu-
rin-NFAT pathway [29]. Recently, da Costa Martins et al. 
demonstrated that miR-199b is a direct calcineurin/NFAT 
target gene, which increases in expression in mouse and 
human heart failure. Additionally, mutant mice overex-
pressing miR-199b, or haploinsufficient for Dyrk1a, are 
sensitized to calcineurin/NFAT signaling or pressure over-
load, and show stress-induced cardiomegaly through re-
duced Dyrk1a expression, implicating miR-199b as a ther-
apeutic target in cardiac hypertrophy [30].  
Moreover, it appears that different miRNAs have distinct 
mechanisms in regulating hypertrophy by the targeting of 
different targets. miR-133 inhibits hypertrophy through tar-
geting RhoA and Cdc42 [31]. It was reported that targets of 
miR-208 include thyroid hormone receptor-associated pro-
tein 1, suggesting that miR-208 initiates cardiomyocyte hy-
pertrophy by regulating triiodothyronine-dependent repres-
sion of the β-myosin heavy chain [32,33]. miR-27a also 
regulates β-myosin heavy chain gene expression by target-
ing TRb1 in cardiomyocytes [34]. It is clear that excessive 
reactive oxygen species (ROS) play a critical role in the 
development of cardiac hypertrophy. In contrast, antioxi-
dants scavenge ROS, thereby maintaining the reduced en-
vironment of cells and inhibiting hypertrophy in the heart. 
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Thioredoxin1 (Trx1) has been shown to function as a major 
antioxidant in the heart and to interact with important sig-
naling molecules and transcription factors, thereby attenu-
ating cardiac hypertrophy [35]. Nevertheless, the signaling 
pathway of Trx1 mediated anti-hypertrophy remains to be 
fully elucidated. Recently, the Sadoshima lab demonstrated 
the involvement of the let-7 family, including miR-98, in 
Trx1 inhibition of cardiac hypertrophy, induced by angio-
tensin II via downregulation of cyclin D2 [36]. 
2.2  Ischemic cardiomyopathy 
Cardiomyocyte death, or apoptosis, is a key cellular event in 
ischemic cardiomyopathy [37]. It is well established that 
multiple genes are aberrantly expressed in infarcted hearts, 
and are responsible for cardiac remodeling following MI or 
I/R injury [38]. Therefore, it is reasonable to hypothesize 
that miRNAs could be involved in ischemic cardiomyopa-
thy (Figure 2). Recently, Ren et al. conducted a novel study 
using a mouse model of cardiac I/R in vivo and ex vivo, to 
determine the miRNA signature in ischemic hearts, and 
found that miR-320 expression was consistently dysregu-
lated following ischemia [39]. They also identified 
heat-shock protein 20 (Hsp20), a known cardioprotective 
protein, as a target of miR-320. Knockdown of endogenous 
miR-320 produced a protective effect against I/R induced 
cell death, by targeting of Hsp20. Further studies from the 
same group showed that the miR-144/451 cluster, regulated 
by GATA4, also provides protection against simulated 
I/R-induced cardiomyocyte death via targeting of the 
CUGBP2-COX-2 pathway. This suggests that GATA4 is  
not only involved in cardiogenesis but myocardial survival 
[40] (Figure 3).  
Investigation of the miRNA expression pattern rat hearts 
at 6 h following MI revealed that miR-21 expression was 
significantly downregulated in infarcted areas but upregu-
lated in border areas [41]. Adenoviral transfer of miR-21 in 
vivo decreased cell apoptosis in the border and infarcted 
areas through its target gene, programmed cell death 4,  
and the activator protein 1 pathway. In vitro experiments 
showed that miR-1 and miR-133 produced opposing effects 
on apoptosis induced by oxidative stress in H9c2 rat ven-
tricular cells, with miR-1 being pro-apoptotic and miR-133 
being anti-apoptotic. Post-transcriptional repression of 
HSP60 and HSP70 by miR-1 and of caspase-9 by miR-13, 
contributes significantly to their opposing actions. miR-1 is 
also associated with the cell death pathway by inhibiting 
translation of insulin-like growth factor-1 [42,43].  
Early ischemia or hypoxia preconditioning is an immedi- 
ate cellular reaction to brief hypoxia/reoxygenation cycles 
that involves de novo protein synthesis, but not mRNA 
synthesis [44]. It is a mechanism required to protect the 
heart against subsequent prolonged ischemia or I/R induced 
damage [45]. The miR-29 family, which is downregulated 
after myocardial infarction, inhibits the expression of sever-
al collagens and extracellular matrix proteins, thereby con-
tributing to scar formation and fibrosis. Similarly, the 
miR-199 family is rapidly downregulated in cardiac myo-
cytes under hypoxic conditions, relieving the repression of 
sirtuin 1 (SIRT1) and hypoxia-inducible factor 1α (HIF-1α) 
in a model of hypoxia preconditioning [46], suggesting that 
miR-199a directly targets and inhibits translation of   
 
 
Figure 2  miRNAs and target genes involved in cardiac hypertrophy. Upregulation or downregulation of a specific miRNA is represented by an upward or 
a downward arrow, respectively. Expression level changes in target genes inversely correlate with that of the targeting miRNA. The targets shown are his-
tone deacetylase 4 (HDAC4), heart- and neural crest derivatives-expressed protein 2 (HAND2), myocyte-specific enhancer factor 2C (mef2c), GATA bind-
ing protein 4 (GATA4), cell division control protein 42 homolog (cdc-42), ras homolog gene family member A (RhoA), thyroid hormone receptor associated 
protein 1 (THRAP1), telomere repeat binding factor 1 (TRB1) and cyclin D2. 
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Figure 3  miRNAs and target genes involved in ischemic cardiomyopathy. The different miRNAs and their targets, involved in cell viability and electrical 
remodeling during ischemic cardiomyopathy. The targets shown are hypoxia-inducible factor 1 (Hif-1), bcl-2 interacting protein (Bim), calcineurin A-alpha 
(CnA-alpha), calcineurin A-beta (CnA-beta), CUG-BP- and ETR-3-like factor 2 (CUGBP2), sirtuin 1 (SirT1), heat shock proteins 20, 60, and 70 (HSP20, 
HSP60, HSP70), caspase 9, connexin 43 (Cx43), inward rectifier potassium channel 2 (Kir2.1) and cardiac voltage-gated potassium channel modulatory  
subunit (Kcnip2). 
HIF-1α and SIRT1. HIF-1α is a master regulator of hypox-
ia-induced gene transcription, and is regulated by a 
post-transcriptional oxygen-sensitive mechanism that trig-
gers its immediate expression subsequent to a drop in oxy-
gen levels. Therefore, miR-199a is likely a key modulator 
of a hypoxia-triggered pathway and an ideal molecule for 
preconditioning the cells against hypoxic insult. Since it has 
been reported that SIRT1 was upregulated, leading to 
deacetylation and inactivation of HIF-1α in hypoxia [47], it 
would be interesting to examine the crosstalk between 
miR-199/SIRT1/HIF1a. 
Recently, the Srivastava Deepark lab reported that 
miRNA-24 expression is downregulated in the ischemic 
border zone of the murine left ventricle following MI [48]. 
miR-24 suppresses cardiomyocyte apoptosis, in part by di-
rect repression of Bim, the BH3-only domain-containing 
protein, which positively regulates apoptosis. In vivo ex-
pression of miR-24 in a mouse MI model inhibited cardio-
myocyte apoptosis, attenuated infarct size and reduced car-
diac dysfunction. This antiapoptotic effect on cardiomyo-
cytes in vivo was partially mediated by Bim. Thus manipu-
lating miRNA levels during stress-induced apoptosis may 
be a novel therapeutic strategy for ischemic cardiomyopa-
thy. 
Other groups have reported that modulation of miR-499 
levels affects apoptosis as well as the severity of myocardial 
infarction and cardiac dysfunction induced by I/R [49]. 
These studies show that the α- and β-isoforms of the cal-
cineurin catalytic subunit are direct targets of miR-499, and 
that miR-499 inhibits cardiomyocyte apoptosis through its 
suppression of calcineurin-mediated dephosphorylation of 
dynamin-related protein-1 (Drp1), thereby decreasing Drp1 
accumulation in mitochondria and Drp1-mediated activation 
of the mitochondrial fission program. Furthermore, they 
found that p53 negatively regulated miR-499 transcription, 
suggesting an interaction between p53, miR-499, calcineu-
rin and Drp1 in the apoptotic program of the heart. Modula-
tion of miR-499 may represent a therapeutic approach to 
treat apoptosis-related cardiac disease, including myocardial 
infarction [49]. 
2.3  Arrhythmia 
A major goal for cardiovascular medicine is to develop im-
proved approaches to prevent electrical remodeling and 
arrhythmias, which are characteristic of ischemic heart dis-
ease [50,51]. 
As miRNAs regulate the cells response to ischemia, they 
also control the expression of molecules involved in regu-
lating action potentials and cardiac conduction. miR-1 is 
upregulated in the heart from patients with coronary artery 
disease (CAD) and in rat ischemic hearts, which correlates  
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to an increase in arrhythmogenesis [52]. Gain-of-function or 
loss-of-function of miR-1 in ischemic rat heart leads to an 
equivalent effect on the frequency of arrhythmias. miR-1 
targets the gap junction proteins Cx43 and Kir2.1, a subunit 
of the K+ channel that mediates IK1. Knockdown of endog-
enous miR-1 could therefore inhibit arrhythmias, whereas 
concomitant knockdown of both Cx43 and Kir2.1 may re-
verse this effect. In support of this, genomic ablation of 
Cx43 [53], or missense mutation or IK1 [54], caused in-
creased episodes of arrhythmias. Interestingly, in contrast to 
their regulation in ischemic conditions, miR-1 and miR-133 
are decreased during cardiac hypertrophy, with miR-1 tar-
geting HCN2 and HCN4, and miR-133 targeting HCN2 
[55]. These proteins are key components of the pacemaker 
channel involved in the hyperpolarization-activated current 
(If). They are also upregulated during cardiac hypertrophy 
and failure, and have been implicated in arrhythmogenesis 
[56]. The downregulation of miR-133 during cardiac hyper-
trophy is also associated with a decrease in Kcnip2, the Ito,f 
accessory subunit, albeit via an indirect mechanism, and is 
accordingly, responsible for prolongation of the QT interval 
[57]. Taken together, miR-1 and miR-133 are multifaceted 
molecules involved in hypertrophic and ischemic heart by 
targeting of a spectrum of mRNAs.  
Recently, it was reported that miR-328 contributes to 
adverse electrical remodeling in atrial fibrillation (AF), par-
tially through targeting L-type Ca2+ channel genes. This 
provides a novel molecular mechanism for AF and impli-
cates miR-328 as a potential therapeutic target for AF [58]. 
3  miRNAs as diagnostic tools for cardiac di- 
sease 
Recent studies have shown that some miRNAs are present 
in circulating blood delivered by exosomes and microparti-
cles [59,60]. Circulating miRNAs have emerged as useful 
diagnostic tools in several diseases [6164]. In cardiovas-
cular disease, circulating miR-208 has been shown in a ro-
dent model of myocardial injury [65]. Additionally, circu-
lating miRNAs have been reported in patients with myocar-
dial infarction [66]. Accordingly, it has been hypothesized 
that miRNAs in the systemic circulation reflect tissue dam-
age, and can be used as biomarkers of myocardial infarction 
[6769]. 
Li et al. demonstrated for the first time, a circulating 
miRNA profile for hypertensive patients, and revealed a 
novel link between HCMV infection and essential hyper-
tension [70]. These findings provide important insights into 
the pathogenesis of essential hypertension. 
Furthermore, a recent report suggests serum levels of 
cardiac-expressed miRNAs react to cardiac injury in a 
manner similar to that of cardiac enzymes. The plasma lev-
els of miRNAs-208b and -499 have been shown to increase 
by more than 1000-fold after myocardial infarction, mirror-
ing the troponin T levels [71]. Viral myocarditis was asso-
ciated with 6- to 30-fold increases in miRNA-499, whereas 
acute heart failure showed only a 2-fold increase. Likewise, 
circulating levels of cell-free miRNA-1 were significantly 
increased in patients with acute myocardial infarction 
(AMI), which positively correlated with serum CK-MB 
levels [72]. Another clinical study showed that miRNA-1, 
miRNA-133a and miRNA-208a in blood from patients with 
AMI were elevated compared with those from patients 
without AMI. Despite these encouraging results, the number 
of samples in the studies is too small to provide definite 
proof of the diagnostic power of miRNA signatures and 
their value for clinical testing of AMI patients. Therefore, 
future prospective trials on large patient cohorts are needed 
to establish miRNAs as a novel biomarker class for AMI. 
Recently, it was reported that elevated levels of circulating 
miR-1 and miR-133a in patients with cardiovascular disease 
originate mainly from the injured myocardium, indicating 
miR-1 and miR-133 in serum may serve as biomarkers for 
myocardial damage [73]. 
4  Future perspectives 
Recent studies provide clear evidence that miRNAs modu-
late a diverse spectrum of cardiac functions with develop-
mental, pathophysiological and clinical implications; how-
ever, many gaps remain in our understanding of miR-
NA-based regulation of gene expression in the normal and 
diseased heart. For example, it will be a great challenge to 
differentiate the mRNAs that are truly relevant to a particu-
lar miRNA-regulated process, since one miRNA may target 
many mRNAs. To aid elucidation of this problem is the 
apparent variability in miRNA function based on physio-
logical context or cell type, making it necessary to define 
the potentially different functions of individual miRNAs in 
different settings. Another important consideration is that 
interactions between multiple miRNAs with common target 
mRNAs are likely to play a major role in gene regulation. 
Thus, it will be of importance to identify sets of miRNAs 
acting cooperatively within the heart. This has significant 
implications in development of miRNA-based therapeutics, 
as administration of miRNA inhibitor cocktails may prove 
more efficacious than targeting a single miRNA. Notwith-
standing these and other hurdles, the rapid technical ad-
vances we are currently witnessing, and the insight that is 
being derived from application of these methods, engenders 
enthusiasm that miRs will lead to “miRacles” rather than a 
“miRage”. 
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